Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Multicenter, Randomized, Controlled, Open-Label Study of the Safety, Efficacy and Pharmacokinetics of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL).

Next Previous
Trial Profile

A Phase II, Multicenter, Randomized, Controlled, Open-Label Study of the Safety, Efficacy and Pharmacokinetics of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Navitoclax (Primary) ; Rituximab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms FRANC
  • Sponsors Genentech

Most Recent Events

  • 10 Dec 2012 Preliminary results presented at the 54th Annual Meeting and Exposition of the American Society of Hematology.
  • 01 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov. (Parent trial: NCT01087151).
  • 07 May 2012 Additional trial location added as reported by ClinicalTrials.gov. (Parent trial: NCT01087151)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top